KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Other Non-Current Liabilities (2017 - 2025)

Aquestive Therapeutics (AQST) has 8 years of Other Non-Current Liabilities data on record, last reported at $7.3 million in Q4 2025.

  • For Q4 2025, Other Non-Current Liabilities rose 203.51% year-over-year to $7.3 million; the TTM value through Dec 2025 reached $7.3 million, up 203.51%, while the annual FY2025 figure was $7.3 million, 203.51% up from the prior year.
  • Other Non-Current Liabilities reached $7.3 million in Q4 2025 per AQST's latest filing, up from $2.1 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $7.3 million in Q4 2025 and bottomed at $1.8 million in Q1 2021.
  • Average Other Non-Current Liabilities over 5 years is $2.3 million, with a median of $2.0 million recorded in 2022.
  • Peak YoY movement for Other Non-Current Liabilities: dropped 18.15% in 2022, then skyrocketed 203.51% in 2025.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $2.5 million in 2021, then decreased by 18.15% to $2.0 million in 2022, then fell by 0.88% to $2.0 million in 2023, then rose by 18.8% to $2.4 million in 2024, then surged by 203.51% to $7.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non-Current Liabilities were $7.3 million in Q4 2025, $2.1 million in Q3 2025, and $2.1 million in Q2 2025.